Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis (original) (raw)
- Original Paper
- Published: 15 May 1998
Oncogene volume 16, pages 2243–2248 (1998)Cite this article
- 718 Accesses
- 154 Citations
- 3 Altmetric
- Metrics details
Abstract
Malignant glioblastomas grow very rapidly and are generally resistant to either DNA-damaging drugs or γ-irradiation. If tumor cells could be made more susceptible to cell death with treatments, this would clearly represent a significant improvement in the success of treatment. Recently, telomerase has become a focus of interest among oncologists as a target for treating cancer cells. Telomerase elongates telomeric DNA repeats (TTAGGG)n and is important in protecting and replicating DNA. The vast majority of tumor cells, indeed, express telomerase activity whereas normal somatic cells, except for a few cells, do not. Since telomerase is essential for protecting DNA, we may be able to make tumors more sensitive to treatments with DNA-damaging drugs by inhibiting telomerase activity. In this study, we used cis-diamminedichloroplatinum (cisplatin)-sensitive U87-MG cells and cisplatin-resistant U251-MG of human malignant glioblastoma cell lines. U87-MG cells did not express telomerase activity, whereas telomerase was highly detected in U251-MG cells. Interestingly, inhibition of telomerase with an antisense telomerase expression vector not only decreased telomerase activity but also increased susceptibility to cisplatin-induced apoptotic cell death in U251-MG cells. These findings suggest that treatment with antisense telomerase may represent a new chemosensitisation for tumors resistant to anticancer drugs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
Author information
Authors and Affiliations
- Department of Neurosciences, Brain Tumor/Neuro-Oncology Center, The Cleveland Clinic Foundation, Cleveland, 44195, Ohio, USA
Yasuko Kondo & John K Cowell - Department of Neurosurgery, Brain Tumor/Neuro-Oncology Center, The Cleveland Clinic Foundation, Cleveland, 44195, Ohio, USA
Seiji Kondo, Talat Haqqi & John K Cowell - Department of Microbiology, The Tokyo Metropolitan Institute of Medical Science, Tokyo, 113, Japan
Yoshikazu Tanaka - RammelKamp Center for Education and Research, MetroHealth Medical Center, Cleveland, 44109, Ohio, USA
Barbara P Barna
Authors
- Yasuko Kondo
You can also search for this author inPubMed Google Scholar - Seiji Kondo
You can also search for this author inPubMed Google Scholar - Yoshikazu Tanaka
You can also search for this author inPubMed Google Scholar - Talat Haqqi
You can also search for this author inPubMed Google Scholar - Barbara P Barna
You can also search for this author inPubMed Google Scholar - John K Cowell
You can also search for this author inPubMed Google Scholar
Rights and permissions
About this article
Cite this article
Kondo, Y., Kondo, S., Tanaka, Y. et al. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis.Oncogene 16, 2243–2248 (1998). https://doi.org/10.1038/sj.onc.1201754
- Received: 18 August 1997
- Revised: 25 November 1997
- Accepted: 27 November 1997
- Published: 15 May 1998
- Issue Date: 30 April 1998
- DOI: https://doi.org/10.1038/sj.onc.1201754